Kailera CEO reports stock option holdings
Kailera Therapeutics, Inc. director, CEO and President Ronald C. Renaud Jr. reports holdings of multiple stock options to buy Common Stock.
Rhea-AI Filing Summary
Kailera Therapeutics, Inc. director, CEO and President Ronald C. Renaud Jr. reports holdings of multiple stock options to buy Common Stock. These options cover blocks of underlying shares at exercise prices of $7.2400 and $5.2500 per share with expiration dates in 2034 and 2035.
Footnotes state that certain options are already fully vested, while others vest over time, typically with 33% or 25% vesting on an initial date and the remainder in substantially equal monthly installments, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Renaud Ronald C JR
Role
CEO & President
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 3,918,467 contracts (Direct)
Footnotes (5)
- F1. The options vested and became exercisable as to 33% of the total shares on September 9, 2025 and thereafter in 24 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
- F2. The stock options are fully vested.
- F3. The options vested and became exercisable as to 33% of the total shares on December 9, 2025 and thereafter in 24 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
- F4. The options vest and become exercisable as to 33% of the total shares on November 5, 2026 and thereafter in 24 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
- F5. The options vest and become exercisable as to 25% of the total shares on November 5, 2026 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Exercise price: $7.2400 per share
Exercise price: $5.2500 per share
Underlying shares: 1,331,116 shares
+4 more
7 metrics
Exercise price
$7.2400 per share
Stock Option (right to buy) for Common Stock
Exercise price
$5.2500 per share
Stock Option (right to buy) for Common Stock
Underlying shares
1,331,116 shares
Stock option with $7.2400 exercise price, expiration 2035-11-05
Underlying shares
574,332 shares
Stock option with $5.2500 exercise price, expiration 2034-12-09
Underlying shares
855,920 shares
Stock option with $5.2500 exercise price, expiration 2034-09-19
Option expiration
2035-11-05
Stock Option (right to buy) at $7.2400 exercise price
Option expiration
2034-12-09
Stock Option (right to buy) at $5.2500 exercise price
Key Terms
Stock Option (right to buy), underlying security, exercise price, expiration date, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
underlying security financial
"underlying_security_title: Common Stock; underlying_security_shares specified"
exercise price financial
"conversion_or_exercise_price: 7.2400 and 5.2500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date regulatory
"expiration_date fields such as 2035-11-05 and 2034-12-09"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest and become exercisable financial
"The options vest and become exercisable as to 33% or 25% of total shares"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the KLRA Form 3 filing show for CEO Ronald Renaud?
The Form 3 shows Ronald C. Renaud Jr., CEO and President of Kailera Therapeutics, holds several stock options to buy Common Stock at fixed exercise prices, with defined expiration dates and vesting schedules tied to his continued service with the company.
What stock option exercise prices are disclosed for KLRA’s CEO?
The filing discloses stock options with exercise prices of $7.2400 and $5.2500 per share. These prices represent the fixed amounts Ronald C. Renaud Jr. must pay per share if he chooses to exercise his options in the future.
When do Ronald Renaud’s KLRA stock options expire?
The reported stock options have expiration dates in 2034 and 2035. After these expiration dates, Ronald C. Renaud Jr. would no longer be able to exercise the respective options to purchase Kailera Therapeutics Common Stock.
How do Ronald Renaud’s Kailera options vest over time?
Footnotes explain that some options are fully vested, while others vest with 33% or 25% of shares on an initial date and the remainder in 24 or 36 substantially equal monthly installments, all conditioned on Ronald C. Renaud Jr.’s continued service on each vesting date.
Are Ronald Renaud’s KLRA options currently exercisable?
The filing notes that certain stock options are already fully vested, meaning they are exercisable, while others will vest and become exercisable over future dates in monthly installments, provided Ronald C. Renaud Jr. continues his service with Kailera Therapeutics.
AI-generated analysis. How Rhea-AI works. Not financial advice.
